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Abstract
Specific inhibitory mechanisms suppress the T-cell response against the hepatitis C virus (HCV) in chronically infected
patients. However, the relative importance of suppression by IL-10, TGF-b and regulatory T-cells and the impact of
pegylated interferon-alpha and ribavirin (PegIFN-a/ribavirin) therapy on these inhibitory mechanisms are still unclear. We
revealed that coregulation of the HCV-specific T-cell responses in blood of 43 chronic HCV patients showed a highly
heterogeneous pattern before, during and after PegIFN-a/ribavirin. Prior to treatment, IL-10 mediated suppression of HCV-
specific IFN-c production in therapy-naive chronic HCV patients was associated with higher HCV-RNA loads, which suggests
that protective antiviral immunity is controlled by IL-10. In addition, as a consequence of PegIFN-a/ribavirin therapy,
negative regulation of especially HCV-specific IFN-c production by TGF-b and IL-10 changed dramatically. Our findings
emphasize the importance of negative regulation for the dysfunctional HCV-specific immunity, which should be considered
in the design of future immunomodulatory therapies.
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Introduction
In the vast majority of patients, the hepatitis C virus (HCV)
causes chronic infection with viral replication primarily in the
liver. The inability to mount strong, broadly targeted and lasting
CD4+ and CD8+ T-cell responses against HCV is considered
crucial for the development and maintenance of this persistent
infection (reviewed in [1,2,3]). Several host and viral mechanisms
have been proposed to contribute to this deficient HCV-specific T-
cell response, including viral escape, impaired antigen presenta-
tion, anergy, exhaustion of the T-cell response mediated via
inhibitory receptors such as PD-1 and Tim-3 [1,2], and active
suppression of virus-specific T-cell responses by regulatory T-cells
(Treg) expressing the transcription factor FoxP3 or by the
immunosuppressive cytokines IL-10 or TGF-b [4]. A recent paper
by Raziorrouh and colleagues suggests that inhibition of IL-10 and
TGF-b simultaneously is the most promising condition to restore
HCV-specific T-cell responses [5].
We and others provided evidence for increased numbers of
FoxP3+Treg in the liver of chronic HCV patients [6,7,8,9]. Treg
in blood have been shown to suppress both HCV-specific
proliferation and IFN-c production by CD4+ and CD8+ T-cells
[10,11,12,13,14]. Moreover, it has been suggested that Treg, at
least partially, control chronic liver inflammation, with higher
Treg suppressive capacity in patients with lower serum alanine
transaminase (ALT) levels [11]. Other studies have shown that
blocking IL-10 or TGF-b can enhance HCV-specific T-cell
proliferation and IFN-c production [15,16,17,18,19]. In addition,
serum IL-10 and TGF-b levels were enhanced in HCV-infected
patients as compared to control individuals, and augmented
production of these inhibitory cytokines by monocytes and T-cells
has been described for HCV-infected patients
[15,17,18,19,20,21,22].
Despite overwhelming evidence on the importance of IL-10,
TGF-b and Treg in controlling immunity to HCV, little
information is available on the coregulation of these regulatory
mechanisms by assessing whether multiple pathways simulta-
neously contribute to impairment of HCV-specific immunity.
Also, the modulation of immunoregulatory pathways by antiviral
therapy of chronic HCV patients has received little attention, but
is highly relevant since it is still under debate whether pegylated
interferon-a and ribavirin (PegIFN-a/ribavirin) therapy restores
the dysfunctional HCV-specific T-cell response or not [23].
In this study, we therefore investigated the relative contribu-
tion of suppression by IL-10, TGF-b and Treg to dysfunctional
HCV-specific immunity in peripheral blood from chronic HCV
patients. In addition, we studied whether this regulation had
clinical implications for these patients. Finally, a detailed
examination of coregulation by multiple inhibitory mechanisms
was conducted during and after PegIFN-a/ribavirin therapy.
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Our findings reveal that regulation of the HCV-specific T-cell
response in chronic HCV patients is highly heterogeneous, as
individuals show distinct patterns of suppression by IL-10, TGF-
b or Treg. However, relatively high viral loads were observed in
therapy-naive chronic HCV patients showing pronounced IL-10
driven suppression of HCV-specific IFN-c production. In
addition, irrespective of viral response to therapy, negative
regulation of especially HCV-specific IFN-c production by TGF-
b and IL-10 changed dramatically as a consequence of PegIFN-
a/ribavirin therapy.
Materials and Methods
Patients, Controls and Antiviral Therapy
Forty-three chronic HCV infected patients were included
(Table 1 and Figure S1 for patient details). Patients were
excluded in case of decompensated liver disease, HBsAg
positivity, or HIV co-infection. Diagnostic core biopsy samples
from 36 of 43 patients, obtained within 3 months prior to start of
therapy, were assessed for fibrosis stage by an experienced liver
pathologist (Metavir score). Twenty-one patients had never
received therapy for HCV before (therapy-naive) and 22 were
nonresponders to previous IFN-a and ribavirin therapy (therapy-
experienced). A cross-sectional immunological study was per-
formed in all 43 patients. In addition, a longitudinal study
followed, in which the 21 therapy-naive patients were investi-
gated at week 4 and 12 during PegIFN-a/ribavirin therapy, and
during the follow-up (FU) period at week 4 and 24 after ending
treatment. Therapy consisted of twice daily orally administered
ribavirin (,65 kg;800 mg/day, 65–80 kg;1000 mg/day, 81–
105 kg;1200 mg, .105 kg;1400 mg, RebetolH, Schering-Plough
now MSD, Houten, the Netherlands) and weekly subcutaneous
injections with pegylated interferon-a-2b (1.5 mg/kg, PegIntronH,
Schering-Plough now MSD). Furthermore, 18 age and sex
matched healthy control subjects were included. The institutional
ethical review board of the Erasmus MC, Rotterdam approved
the clinical protocols, and written informed consent was obtained
from all individuals prior to their inclusion. The study was
conducted according to the principles expressed in the Declara-
tion of Helsinki.
In vitro Quantification of HCV-specific T-cell Proliferation
and IFN-c Production
Peripheral blood mononuclear cells (PBMC) were isolated
from venous blood by ficoll separation (Ficoll-PaqueTM plus,
Amersham, Buckinghamshire, UK) and immediately cultured in
quadruplets in 96-well round-bottom plates (2x105 cells in
200 mL). Cells were always stimulated with the same pool of
overlapping peptides (1 mg/mL per individual peptide; in total
361 individual peptides spanning the core, NS3, NS4, NS5a and
NS5b HCV genome; clone J4, genotype 1b; BEI Resources,
Manassas, USA), anti-CD3 antibody (1 mg/mL; OKT-3; Jans-
sen-Cilag, Tilburg, the Netherlands), CMV antigens (34 mg/mL;
AD-169; Microbix, Toronto, Canada) or no stimulus. DMSO
concentrations in all cultures did not exceed 0.5%, which is the
concentration generally considered to be acceptable [24]. Culture
medium was RPMI 1640 supplemented with L-glutamin,
Penicillin-Streptomycin, HEPES, and 5% human serum (all
from Lonza, Verviers, Belgium), anti-CD28 (1 mg/mL; CD28.2;
eBioscience, San Diego, USA) and anti-CD49d antibody (1 mg/
mL; 9F10; eBioscience). After culturing for 3 days, 100 mL
supernatant was collected from each well, stored at 280uC, and
replaced by fresh culture medium. Supernatants were not pooled
and IFN-c levels were determined in quadruplets in these
supernatants by ELISA (Ready Set Go; eBioscience). After
stimulation for 5 days, cells were pulsed for 16h with [3H]-
thymidine (0.5 mCi/well; Amersham, Little Chalfont, UK).
Proliferation was determined as counts per minute (cpm) by
liquid scintillation. For HCV-specific T-cell proliferation and
IFN-c assays, results were considered positive when more than
500 counts or 100 pg/mL were detected above background,
which corresponded to 3 SD above any response observed in
healthy controls (data not shown).
Blocking and Depletion Experiments
Neutralizing antibodies against the IL-10 receptor (IL-10R,
5 mg/mL; 3F9; Biolegend, San Diego, USA), or TGF-b (5 mg/mL;
1D11, kindly provided by Dr. Boon, Bioceros, Utrecht, the
Netherlands) were added to the cultures and HCV-specific assays
were performed as described above. In addition, assays were
performed with PBMC from which CD25hi cells were depleted
using CD25 magnetic beads (Miltenyi Biotech, Bergisch Glad-
bach, Germany). This strategy allowed depletion of at least 80% of
CD4+CD25+FoxP3+ Treg (data not shown). HCV-specific re-
sponses were considered regulated by Treg, TGF-b or IL-10 when
proliferation or IFN-c levels increased by at least 500 cpm or
100 pg/mL, respectively.
In vitro Quantification of Circulating IP-10, IL-10, TGF-b
and Treg levels
Serum IP-10, IL-10 and latent TGF-b levels were determined
by ELISA (IP-10: Quantikine Kit, IL-10; Quantikine-HS-kit,
RnD, Minneapolis, USA and TGF-b; Ready–Set-Go;
eBioscience). To determine the frequency and phenotype of
circulating FoxP3+Treg cells, venous blood samples were fixed and
erythrocytes lysed using FixPermTM reagent (eBioscience). Sam-
ples were stained with antibodies against CD25-PE-Cy7 (2A3;
BD), FoxP3-APC (PCH101; eBioscience), CD4-APC-H7 (SK3;
BD) and CD3-AmCyan (SK7; BD). Cell acquisition was
performed on a FACSCanto II flowcytometer (BD), and analyzed
using FacsDivaTM software (BD). For analysis, the gating strategy
used to identify FoxP3+Treg cells was identical as used in our
previous studies [9,25]. Furthermore, all CD4+CD25+FoxP3+-
Treg did not express CD127 (data not shown). The gates were set
on the basis of isotype antibody controls, where appropriate.
Virological Assessment
Serum HCV-RNA levels were determined by quantitative PCR
(CobasH Ampliprep/CobasH TaqManH HCV test (limit of
detection ,15 IU/mL, Roche Diagnostics, the Netherlands).
HCV genotypes were determined by an in-house developed
sequence analysis assay (Department of Virology, Erasmus MC).
IL-10 and TGF-b Genotype Determination
The IL28B SNP rs12979860, IL10 SNP rs1800896 and TGF-b
SNP rs1800471 variants were determined using competitive allele-
specific PCR (KASP; kBioscience Hoddesdon, UK).
Data Analysis
Data are depicted as mean 61 SD and unpaired data were
compared using Student’s t-test or the Mann Whitney U test for
nonparametric data. Correlations between immunological and
clinical parameters were calculated using the Spearman correla-
tion test. SPSS 17.0 for Windows (SPSS, Chicago, USA) was used
for these analyses. All p-values were two-tailed and considered
significant if ,0.05.
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Table 1. Patient characteristics.
Therapy Sustained SNP SNP SNP
Study
number Sex Age
Liver
fibrosis
Geno
type HCV RNA ALT naı¨ve Viral IL-10 TGF-b IL-28B IP-10
(M/F) (years) (Metavir) (IU/mL) (U/L) Response (pg/ml)
1 F 57 3 1 1.16107 150 Yes Yes GG GG TC 698
2 F 37 n.d. 3 3.26103 79 Yes Yes GA GG TT 206
3 M 54 1 1 2.76107 49 Yes No GA GG TC 99
4 F 27 1 1 3.76102 34 Yes Yes GG GG CC 153
5 M 48 2 3 1.16105 146 Yes Yes AA GG CC 108
6 M 51 2 1 3.16106 46 Yes No GA GG TC 89
7 M 52 2 3 1.56105 41 Yes Yes AA GG TC 113
8 M 34 2 1 3.86106 103 Yes Yes AA n.a. CC 237
9 M 56 2 1 6.56106 157 Yes No GA GG TT 596
10 F 57 4 1 7.76105 17 Yes No GA GG TC 257
11 M 45 2 1 4.56106 55 Yes Yes GA GC CC 922
12 M 47 1 1 4.56105 227 Yes Yes GA GG TC 319
13 F 41 1 3 8.66105 46 Yes Yes GA GG TC 372
14 M 60 3 3 3.26106 164 Yes Yes n.a. GC CC 141
15 M 40 2 1 2.26104 58 Yes No GA GG CC 396
16 F 40 3 1 3.16105 120 Yes No GA GG TT 590
17 M 45 n.d. 1 1.16107 36 Yes No GA GG TC 1248
18 F 58 4 1 1.66105 179 Yes Yes AA GG TC 653
19 M 57 0 1 7.26106 48 Yes No AA GG TC 153
20 M 42 1 1 1.56106 65 Yes Yes AA GC TC 377
21 F 42 n.d. 1 3.36106 107 Yes Yes GG GG TC 993
22 M 47 1 1 5.36105 144 No n.a. GA GC TC 277
23 M 43 4 1 3.46105 89 No n.a. GA GG TC 233
24 F 50 3 1 6.16105 111 No n.a. AA GG TT 581
25 F 55 0 1 5.56105 59 No n.a. n.a. n.a. TC 875
26 M 44 0 1 6.76105 33 No n.a. GG GG TC 127
27 F 48 1 1 6.06105 61 No n.a. GA GG TT 622
28 M 45 3 1 1.66106 57 No n.a. AA GG TT 289
29 M 49 0 1 3.96105 48 No n.a. GA GG TC 469
30 M 36 4 1 9.36105 98 No n.a. GA GG TT 818
31 M 48 3 1 2.66106 122 No n.a. GG GG TC 208
32 M 41 4 1 1.96105 120 No n.a. GA GG TC 357
33 M 44 n.d. 1 6.26102 44 No n.a. AA GG CC 54
34 F 53 n.d. 1 2.46106 77 No n.a. AA GG CC 151
35 M 43 2 1 6.16105 224 No n.a. GA GG TC .1500
36 M 50 n.d. 1 1.86105 55 No n.a. GA GG TC 266
37 M 41 2 1 3.46105 67 No n.a. GA GG TT 369
38 M 59 3 1 9.36105 84 No n.a. GG GC CC 308
39 M 39 2 1 8.36105 53 No n.a. AA GG TC 286
40 F 46 0 1 5.26104 74 No n.a. AA GG TC .1500
41 M 41 2 1 4.56105 57 No n.a. AA GG TT 680
42 M 44 n.d. 4 2.36105 33 No n.a. GA GG TC 140
43 M 48 0 1 2.46106 56 No n.a. GA GG TC 359
Abbreviations: n.d., not determined within 3 months before start of therapy; n.a., not applicable.
doi:10.1371/journal.pone.0049389.t001
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Results
HCV-specific T-cell Proliferation and IFN-c Production are
Weak or Undetectable in Therapy-naive and PegIFN-a/
ribavirin Therapy-experienced Chronic HCV Patients
The strength of T-cell responses to HCV antigens was evaluated
in 43 chronic HCV patients. In line with previous reports
(reviewed in [1,2]) upon stimulation of PBMC with a cocktail of
HCV peptides, proliferative responses were weak in 24 out of 43
chronic HCV patients, and undetectable in the remaining 19
(Figure 1A). Despite the fact that HCV-specific T-cell responses
were weak or undetectable, up to 100 fold stronger CMV-specific
T-cell proliferation was detected in PBMC of 40 out of 43 chronic
HCV patients (Figure 1B). HCV-specific IFN-c production was
also low to undetectable in most patients, as only 12 out of 43
patients showed substantial IFN-c production (Figure 1C). Al-
though we mainly analyzed overall T cell responses in our study,
in those chronic HCV patients with exceptionally strong HCV-
specific responses, HCV peptides were able to elicit simultaneous
proliferation and IFN-c production by both CD4+ and CD8+ T
cells (Figure S2). PBMC from healthy individuals did not respond
to the HCV peptide pool (data not shown).
Multiple Regulatory Mechanisms Suppress HCV-specific
T-cell Proliferation in Chronic HCV Patients
Next, we evaluated the regulation by IL-10, TGF-b and Treg
on the dysfunctional HCV-specific T-cell reactivity in the 43
patients. For this purpose, we first determined HCV-specific T-cell
proliferation with or without in vitro blockade of the IL-10R or
TGF-b using neutralizing antibodies, or depletion of
CD4+CD25hiTreg. In this cross-sectional study, suppression by
IL-10, TGF-b or Treg of HCV-specific T-cell proliferation was
operational in respectively 6, 11 and 19 out of 43 patients
(Figure 2A). We are confident that we analyzed the impact of
depletion of CD4+CD25hi Treg and not the depletion of
CD8+CD25hiFoxP3+ Treg, as CD8+CD25hi Treg were virtually
absent in peripheral blood. The regulation of HCV-specific
proliferation was highly heterogeneous in that each of 8 possible
combinations of regulatory mechanisms occurred, albeit some at
low frequency. Furthermore, no dominant pattern could be
identified, and regulation of HCV-specific proliferation and IFN-c
production were often by different mechanisms. Interestingly,
HCV-specific T-cell proliferation was not affected by a previous
nonresponse to PegIFN-a/ribavirin therapy, as the frequency
(Figure 2A) and strength (Figure S3) of regulation by IL-10, TGF-
b and Treg was comparable to therapy-naive chronic HCV
patients.
Regulation of HCV-specific IFN-c Production Differs
between PegIFN-a/ribavirin Experienced and Therapy-
naive Chronic HCV Patients
Next, we studied whether HCV-specific IFN-c production in
chronic HCV patients was suppressed by multiple regulatory
mechanisms similar as the heterogeneous regulation of HCV-
specific T-cell proliferation. As shown in Figure 2B, blocking the
suppressive effects of IL-10, TGF-b, or Treg enhanced HCV-
specific IFN-c production, albeit that a different pattern of
regulation was observed between therapy-naive and PegIFN-a/
ribavirin experienced chronic HCV patients. For therapy-naive
chronic HCV patients, similar as for T-cell proliferation,
regulation of HCV-specific IFN-c production was highly hetero-
geneous.
In sharp contrast, in PegIFN-a/ribavirin experienced chronic
HCV patients IL-10 mediated regulation of IFN-c production was
absent (Figure 2B). Moreover, different from therapy-naive
patients, TGF-b suppressed HCV-specific IFN-c production in
the majority of therapy-experienced chronic HCV patients
(Figure 2B; respectively 5 out of 21 and 14 out of 22) with strong
increments in IFN-c levels detected after blocking TGF-b (Figure
S3B). Regulation by Treg was also observed in PegIFN-a/
ribavirin experienced patients, however at similar rates and with
comparable strength as for therapy-naive patients.
Levels of circulating TGF-b and Treg frequencies in blood were
similar for therapy-naive patients, PegIFN-a/ribavirin experi-
enced patients and healthy controls (Figure 2C) and did not
correlate with HCV-specific T-cell reactivity (data not shown).
Also, no correlation was observed between the levels of circulating
TGF-b and Treg frequencies in blood and the effects of TGF-b
neutralization or Treg depletion. In contrast to healthy individ-
uals, enhanced serum IL-10 was measured in some, but not all,
HCV-infected patients (Figure 2C). However, the presence of
serum IL-10 did not correlate with clinical parameters such as
HCV-RNA or ALT levels, or with the presence of IL-10
dependent regulation of HCV-specific T-cell proliferation or
IFN-c production (data not shown).
IL-10 Mediated Suppression of HCV-specific IFN-c
Production Affects the Level of HCV Replication in
Therapy-naive Patients
To identify mechanisms explaining clinical differences between
patients, we questioned whether regulation of HCV-specific T-cell
reactivity was related to disease parameters. As shown in
Figure 3A, HCV-RNA levels in therapy-naive patients were
significantly higher in case of active IL-10 mediated suppression of
HCV-specific IFN-c production, as opposed to the lower HCV-
RNA levels observed in therapy-naive patients without IL-10
driven regulation of HCV-specific IFN-c production (p,0.004).
Other significant associations between regulation by IL-10, TGF-
b, or Treg and disease parameters such as time-since-infection,
ALT levels, and liver fibrosis grade were not found, neither for the
whole group of 43 chronic HCV patients, nor for therapy-naive or
PegIFN-a/ribavirin experienced patients separately (data not
shown). To increase the power of our analysis, we included a
group of 23 additional chronic HCV patients (Table S1 for patient
characteristics), and retested for correlation with disease param-
eters. Re-analysis of this extended data-set (n = 66) revealed similar
results (data not shown).
Irrespective of Viral Outcome, Regulation of HCV-specific
IFN-c Production by TGF-b Increases During and up to 24
Weeks After PegIFN-a/ribavirin Therapy
There is an ongoing debate whether PegIFN-a/ribavirin
therapy restores the dysfunctional HCV-specific T-cell response
due to removal of antigenic pressure on immune cells [23]. If this
is the case, the dynamics in activity of regulatory pathways may
explain this restoration. To examine this in our cohort, we
prospectively examined the type and degree of regulation of HCV-
specific T-cell responses at various timepoints during, and up to 24
weeks after therapy in 21 therapy-naive patients receiving PegIFN-
a/ribavirin therapy for the first time. When pretreatment and 24
weeks after therapy were compared, regulation of HCV-specific T-
cell proliferation by IL-10 was never observed at both timepoints
and only present in a small proportion of patients (Figure 3B). Also
during therapy, only a minority of patients showed regulation of
HCV-specific T-cell proliferation by IL-10. At the same time, IL-
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10 driven suppression of HCV-specific IFN-c production
remained present during and shortly after therapy, but decreased
24 weeks after therapy, both in patients achieving a sustained viral
response (SVR) and in non-SVR patients (Figure 3C and Figure
S4). Regulation of HCV-specific T-cell reactivity by IL-10 was not
related to the outcome of therapy, as regulation of HCV-specific
T-cell proliferation and IFN-c production was equally distributed
among the 13 SVR patients and 8 non-SVR patients.
Suppression of HCV-specific T-cell proliferation by TGF-b was
infrequent during and 24 weeks after therapy as it was before
therapy. Only at 4 weeks after end of therapy, a transient increase
in regulation of HCV-specific T-cell proliferation by TGF-b was
observed (Figure 4A). In contrast, although serum TGF-b levels
remained unchanged (data not shown), TGF-b driven regulation
of HCV-specific IFN-c production increased gradually during
therapy and continued to increase up to 24 weeks after therapy,
when 16 out of 21 patients showed regulation by TGF-b
(Figure 4B). Twenty-four weeks after therapy, regulation was not
only most frequent, but also strong as TGF-b neutralization
resulted in a mean increase of HCV-specific IFN-c production of
3111 pg/mL.
Discussion
This study establishes that the regulation by IL-10, TGF-b and
Treg of dysfunctional HCV-specific immunity in chronic HCV
patients is highly heterogeneous. However, two clear differences
between PegIFN-a/ribavirin experienced patients and therapy-
naive patients could be distinguished. In therapy-experienced
chronic HCV patients, regulation of HCV-specific IFN-c produc-
tion by TGF-b was dominant, while regulation by IL-10 was
absent. In contrast, in about half of therapy-naive chronic HCV
Figure 1. Chronic HCV infected patients show dysfunctional HCV-specific T-cell responses. Forty-three chronic HCV-infected patients
were investigated (21 therapy-naive and 22 PegIFN-a/ribavirin experienced). T-cell proliferation (cpm) to HCV (A) or CMV (B) were determined at day
5 upon stimulation of PBMC, and IFN-c production (C) at day 3. The sensitivity of the IFN-c ELISA was 20 pg/mL, and therefore data of 17 patients are
shown as one single horizontal line in the graph. For all graphs, patients showing significant responses are depicted to the left (YES) and those
without are shown to the right (NO).
doi:10.1371/journal.pone.0049389.g001
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patients, especially those with a high viral load, IL-10 was involved
in the regulation of HCV-specific IFN-c production. Upon
treatment with PegIFN-a/ribavirin of previously therapy-naive
patients, regulation by TGF-b of HCV-specific IFN-c production
gradually increased over time and reached a maximum at the end
of follow-up at 24 weeks after therapy.
The present study clearly shows that Treg, TGF-b and IL-10 all
contribute to the suppression of HCV-specific T-cell proliferation
in chronic HCV patients. Our data suggest that regulation of
HCV-specific T cells by IL-10, TGF-b or Treg was specific for
HCV, as the pattern of regulation of HCV-specific T cells differed
from regulation of CMV-specific T cells (Figure S5). Although our
findings on the regulation of virus-specific T cell proliferation
suggest that IL-10 is more important to control CMV responses as
compared to HCV responses, one should be aware that the nature
of the virus antigen differs (peptide pool versus CMV lysate).
Importantly, also in those patients in whom HCV-specific T-cell
proliferation or IFN-c production was not observed upon
stimulation with HCV peptides alone, these responses could be
revived by blocking one of the inhibitory mechanisms studied.
However, we now show that the importance of the specific
pathways to inhibit HCV-specific immunity differs between
patients and no dominant regulatory mechanism can be identified.
This strong heterogeneity of regulation of HCV-specific immunity
has not been emphasized before. In contrast, previous reports
suggested exclusive suppression of HCV-specific immune respons-
es by Treg, TGF-b or IL-10 [10,11,12,13,14,16,18] and to our
knowledge only three previous reports showed involvement of
both TGF-b and IL-10 in the suppression of HCV-specific
immunity [17,19]. In addition, the recent paper by Raziorrouh
and colleagues suggests that inhibition of IL-10 and TGF-b
simultaneously is the most promising condition to restore HCV-
specific T-cell responses [5]. Our present study is complementary
and is in agreement with these findings when evaluating the
mechanisms of negative regulation at baseline, although we did
not block IL-10 and TGF-b simultaneously. Importantly, in our
study, we further emphasize the heterogeneous nature of the
regulatory pathways, and also the modulation of the regulatory
Figure 2. Multiple regulatory mechanisms control HCV-specific T-cell reactivity in PBMC from chronic HCV infected patients. (A)
Individual data of 43 patients on regulation of HCV-specific T- cell proliferation and (B) IFN-c production are shown (number 1–21 are therapy-naive;
22–43 PegIFN-a/ribavirin experienced patients). Patient numbers are identical to the numbers in Table 1, and numbers of non-genotype 1 patients
are depicted in red. Red squares depict HCV-specific T-cell proliferation or IFN-c production without in vitro blockade of any regulatory pathway
(baseline response). Green squares reflect patients with a significant increase of HCV-specific responses after IL-10R or TGF-b neutralization, or
depletion of Treg. White squares reflect the absence of a baseline response or regulation. The experiments were performed similar as in Figure 1A.
Histograms to the right hand side show percentages of patients with HCV-specific responses at baseline, or significant regulation of these responses
by respectively IL-10, TGF-b or Treg. The quantitative data of T cell proliferation and IFN-c production is presented as cpm and IFN-c levels in Figure
S3 to allow evaluation of the strength of the individual responses. (C) Serum IL-10 and TGF-b levels and blood CD4+FoxP3+ Treg as a proportion of
leukocytes are presented in naı¨ve and treatment experienced patients and healthy controls.
doi:10.1371/journal.pone.0049389.g002
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mechanisms during the course of IFN-a-based antiviral therapy.
Differential expression of IL-10 or TGF-b receptors on HCV-
specific cells between different patients and between different
antigen specificities is a possible mechanism responsible for the
heterogeneity of regulation. The heterogeneous character of
regulation of HCV-specific T-cell immunity is reminiscent of the
expression of exhaustion markers and their functional synergy to
control HCV-specific T-cell immunity [26–27].
One possible explanation for the heterogeneity of regulation is
that patients are at different phases of disease, and vary greatly in
level of viral replication and viral sequences, liver inflammation,
pathology and other disease parameters. Additionally, in our study
cohort consisting of 43 patients, 6 non-HCV genotype-1 patients
were included, and we can not exclude that PBMC from these
patients may show a distinct cross-reactivity to the peptides
resulting in heterogeneity in immune responses. We suggest that
time-since-infection, and subsequent differences in phase of disease
are important factors explaining the heterogeneous regulation of
T-cell responses in chronic and therapy-induced resolved HCV
infection. This has been proposed before as a general model for
regulation of immunity to chronic infections [4]. In line with this
concept, our study shows that HCV-RNA loads were higher in
chronic HCV patients showing active IL-10 mediated suppression
of HCV-specific IFN-c production. We cannot explain why
individual patients differ with respect to the usage of IL-10
pathways leading to differences in HCV-RNA levels, but genetic
polymorphisms in the IL-10 gene may be important. Although we
determined the IL-28B, IL-10 and TGF-b gene polymorphisms
(see Table 1), our study cohort was too small to draw firm
conclusions on the importance of these SNPs in modulating T cell
reactivity to HCV. A larger patient cohort and more detailed
information on time-since-infection is needed to establish further
relations between disease parameters and regulation of HCV-
specific immunity.
This is the first prospective study examining PegIFN-a/ribavirin
therapy-induced effects on IL-10 and TGF-b mediated suppres-
sion of HCV-specific immune responses. We observed that upon
antiviral treatment IL-10 mediated regulation was diminished and
Figure 3. Regulation of HCV-specific immunity by IL-10 is associated with higher HCV-RNA levels in therapy-naive patients,
however not linked to success of PegIFN-a/ribavirin therapy. (A) HCV-RNA levels of 21 therapy-naive chronic HCV patients with or without
regulation by IL-10 of HCV-specific IFN-c production. (B) Individual data of 21 previously therapy-naive chronic HCV patients before and 24 weeks
after ending therapy are shown. Patients 1–13 showed an SVR, patients 14–21 did not achieve an SVR (non-SVR). (A) Green squares reflect patients
with a significant increase in either HCV-specific proliferation or (B) IFN-c production after neutralization of the IL-10R. White squares reflect the
absence of regulation by IL-10. Grey squares reflect missing data. Histograms to the right side show percentages of patients with significant IL-10
driven regulation of HCV-specific responses at the indicated timepoints.
doi:10.1371/journal.pone.0049389.g003
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TGF-b mediated regulation strongly enhanced. Irrespective of
response to therapy, IL-10 driven regulation of HCV-specific IFN-
c production was decreased 24 weeks after therapy, albeit that a
small group of patients still showed IL-10 regulation. Possibly, a
longer follow-up is needed to loose IL-10 driven regulation of
HCV-specific IFN-c production, as our cohort of 22 chronic HCV
infected patients with a previous nonresponse to therapy showed
an absence of IL-10 driven regulation of HCV-specific IFN-c
production (Figure 2b). As mentioned above, IL-10 driven
regulation may allow higher levels of HCV replication in
therapy-naive chronic HCV patients. It seems that exposure to
PegIFNa/ribavirin therapy diminishes the importance of this IL-
10 mediated suppression of anti-HCV immunity irrespective of
virologic response to therapy.
Our prospective data showed that when therapy-naive patients
were treated with PegIFN-a/ribavirin, regulation by TGF-b of
HCV-specific IFN-c production gradually increased over time,
and reached a maximum at the end of follow-up at 24 weeks after
therapy. Thus, exposure to PegIFN-a/ribavirin increases the
frequency of TGF-b driven regulation of HCV-specific IFN-c
production. This may be a direct effect of PegIFN-a/ribavirin
therapy and not secondary to a decrease in HCV-RNA load, since
regulation by TGF-b increases gradually in both SVR and non-
SVR patients. Our finding that TGF-b driven regulation of HCV-
specific IFN-c production increases induced by PegIFN-a/
ribavirin, is supported by our cross-sectional data on previous
nonresponders to therapy, who still show frequent regulation by
TGF-b. Also when these previous nonresponders are retreated,
regulation by TGF-b remains dominant and regulation by IL-10
remains rare (data not shown). At present there is only limited
information available on the interplay between IFN-a and TGF-b
responses. However, in studies using rats, it was shown that IFN-a-
2b can increase TGF-b1 production [28] and that positive cross
talk exists between IFN-a and TGF-b1 signaling [29]. These
observations may at least in part explain our findings since they
are in line with the more frequent regulation of T cell responses by
TGF-b we describe in our manuscript. The importance of TGF-b
in the nonresponse to IFN-a-based treatment of chronic HCV
patients has been reported before. It has been demonstrated, using
gene expression analysis, that TGF-b pathways – similar to the
interferon stimulated gene pathways– are already upregulated at
baseline in non-responder patients [30].
For SVR patients, TGF-b mediated suppression of HCV-
specific IFN-c production by memory T-cells was unexpected,
since the activity of TGF-b in HCV is often linked to liver
fibrogenesis [31] and SVR is associated with a reduction in fibrosis
[32]. Importantly, total TGF-b concentrations in serum were
similar before and after successful HCV eradication (data not
shown), in contrast to older studies reporting reduced serum TGF-
b levels in SVR patients [33,34]. Our study indicates a role for
TGF-b as a regulatory cytokine suppressing the pro-inflammatory
responses after PegIFN-a/ribavirin therapy, irrespective of viral
response, rather than a cytokine promoting liver fibrogenesis. The
in vivo situation where chronic HCV patients are treated for
prolonged periods of time with PegIFN-a/ribavirin leads to
reduction of HCV-RNA levels and ideally to eradication of the
Figure 4. Irrespective of viral outcome, regulation of HCV-specific IFN-c production by TGF-b increases during and up to 24 weeks
after PegIFN-a/ribavirin therapy. Individual data of previously therapy-naive chronic HCV patients before, during and after therapy are shown.
Patients 1–13 showed an SVR, patients 14–21 did not achieve an SVR (non-SVR). (A) Green squares reflect patients with a significant increase in either
HCV-specific proliferation or (B) IFN-c production after neutralization of TGF-b. White squares reflect the absence of regulation by TGF-b. Grey squares
reflect missing data. Histograms to the right side show percentages of patients with significant TGF-b driven regulation of HCV-specific responses at
the indicated timepoints.
doi:10.1371/journal.pone.0049389.g004
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virus and reduction of inflammatory processes. However, since the
receptors for IFN-a are expressed on most leukocyte populations
as well as non-leukocytes, the effects are broad and the antiviral
mechanisms of action of IFN-a are numerous. Since the in vivo
situation is extremely complex, in vitro experiments to corroborate
the effect of PegIFN-a/ribavirin on TGF-b production will always
be an oversimplification of the situation in patients. Also, it is
worth mentioning that in our experimental setup, the source of
TGF-b and IL-10 is unknown and not necessarily derived from T
cells.
Treg mediated regulation of HCV-specific proliferation grad-
ually decreased during and after PegIFN-a/ribavirin therapy in
both SVR and non-SVR patients, while regulation by Treg of
HCV-specific IFN-c production remained relatively stable (Figure
S6). These data are in line with the only previous study that
prospectively examined regulation by Treg during PegIFN-a/
ribavirin therapy that did not find a role for peripheral blood Treg
in the response to treatment [35]. As the actual depletion of
CD4+CD25+FoxP3+ Treg using CD25 magnetic beads was at
least 80%, a small fraction of Treg remained present, Therefore,
our study may underestimate the importance of Treg in regulating
HCV-specific responses to a certain extent. In future studies,
depletion of Treg by flowcytometric sorting and inclusion of
CD127 can improve this percentage. Moreover, in contrast to
previous studies, we did not observe increased numbers of Treg in
HCV-infected patients compared to healthy individuals, which
may be due to the inclusion of the FoxP3 marker to define Treg in
contrast to other studies [10,11,12,13]. In contrast to blood, we
recently showed that intrahepatic CD4+CD25+FoxP3+ Treg
increased during therapy, and their numbers remained elevated
for more than 6 months after therapy-induced viral clearance in
the majority of patients [9].
Additional research on the complex process of heterogeneous
coregulation is required to understand the dysfunctional HCV-
specific immunity in chronic HCV patients. In this, the use of CD4
tetramers, which have recently been described [36], would be
instrumental to obtain more detailed mechanistic data, for
instance on the regulation of IL-10 and TGF-b receptor
expression on HCV-specific T cells. Further evaluation of multiple
regulatory mechanisms may explain variability in immunopathol-
ogy between chronic HCV patients, and optimization of
immunotherapy should take into account the substantial differ-
ences between patients with respect to inhibitory processes
preventing protective immunity against HCV.
Supporting Information
Figure S1 Flowchart of patients included in the study.
43 Chronic HCV infected patients were included: therapy-naive
(n = 21) and PegIFN-a/ribavirin experienced (n= 22). A cross-
sectional immunological study was carried out on these 43
patients. Therapy-naive chronic HCV patients received standard
PegIFN-a/ribavirin therapy. Thirteen patients achieved an SVR,
as they remained HCV-RNA negative 6 months after end of
therapy. Eight patients showed a nonresponse to therapy, and did
not become HCV-RNA negative. A longitudinal immunological
study was carried out in which the 21 therapy-naive patients were
followed up during and up to 24 weeks after therapy.
(PDF)
Figure S2 HCV peptides can elicit simultaneous prolif-
eration and IFN-c production by both CD4+ and CD8+ T
cells. Frequencies of IFN-c producing HCV-specific CD4+ or
CD8+ T cells were determined using flowcytometry. PBMC
labelled with CFSE (0.25 mM; Invitrogen) were cultured in 24-well
flat bottom plates (106 cells in 1 mL) in the presence or absence of
the HCV peptide pool. At day 6, cells were restimulated in 24-well
plates coated with anti-CD3 (5 mg/mL; OKT-3, Janssen-Cilag) for
2 hours and an additional 3 hours with Brefeldin-A (10 mg/mL;
Sigma-Aldrich). Cells were fixed (2% formaldehyde, 20 minutes),
permeabilized (0.5% saponin) and labelled with CD4-APC-H7
(SK3; BD, San Jose, USA), CD8-PerCP (RPA-T8; eBioscience)
and IFN-c-PE-Cy7 (4S.B3; BD).
(PDF)
Figure S3 Multiple regulatory mechanisms control
HCV-specific T-cell reactivity in PBMC from chronic
HCV infected patients. Quantitative data on (A) regulation of
HCV-specific T-cell proliferation (cpm) and (B) IFN-c production
(pg/mL) are shown for 43 chronic HCV patients (21 therapy-naive
and 22 PegIFN-a/ribavirin therapy experienced). Graphs to the
left, middle and right, respectively, show the effects of neutrali-
zation of the IL-10R or TGF-b, or depletion of Treg. The
experiments were performed similar as in Figure 1A and 2. For all
graphs, the number of patients with and without regulation is
given (YES, n= number and NO, n= number, respectively). Data
before and after neutralization of the IL-10R or TGF-b, or
depletion of Treg were compared using Student’s t-test for paired
data or the Wilcoxon matched pairs test, where appropriate.
(PDF)
Figure S4 Frequency of regulation by IL-10 of HCV-
specific T-cell proliferation is stable during PegIFN-a/
ribavirin therapy and regulation of HCV-specific IFN-c
production by IL-10 is decreased at 24 weeks after
PegIFN-a/ribavirin therapy. Individual patient data before
(T= 0), week 4 or 12 during (T= 4 and T=12, respectively) and 4
or 24 weeks after PegIFN-a/ribavirin therapy (T= 4FU and
T=24FU, respectively) are shown for 21 previously therapy-naive
chronic HCV patients. Patients 1 to 13 showed a sustained viral
response, patients 14 to 21 a viral nonresponse. (A) Green squares
reflect patients with a significant increase in either HCV-specific
proliferation or (B) IFN-c production after neutralization of IL-
10R. White squares reflect the absence of regulation by IL-10.
Grey squares reflect missing data. Histograms to the right side
show percentages of patients with significant IL-10 driven
regulation of HCV-specific responses at the indicated timepoints.
(PDF)
Figure S5 Regulation of HCV-specific T cells by IL-10,
TGF-b or Treg was specific for HCV, as the pattern of
regulation differed completely from regulation of CMV-
specific T cells. (A) Individual data of 43 patients on regulation
of HCV-specific T- cell proliferation and (B) regulation of CMV-
specific T- cell proliferation are shown (number 1–21 are therapy-
naive; 22–43 PegIFN-a/ribavirin experienced patients). Patient
numbers are identical to the numbers in the Table 1 and numbers
of non-genotype 1 patients are depicted in red. Red squares depict
CMV or HCV-specific T-cell proliferation without in vitro
blockade of any regulatory pathway (baseline response). Green
squares reflect patients with a significant increase of antigen-
specific responses after IL-10R or TGF-b neutralization, or
depletion of Treg. White squares reflect the absence of a baseline
response or regulation. Grey squares reflect the absence of data.
The experiments were performed similar as in Figure 1A.
(PDF)
Figure S6 Irrespective of viral outcome, regulation of
HCV-specific T-cell proliferation by Treg decreases
during and up to 24 weeks after PegIFN-a/ribavirin
therapy. Individual patient data before (T= 0), week 4 or 12
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during (T=4 and T=12, respectively) and 4 or 24 weeks after
PegIFN-a/ribavirin therapy (T=4FU and T=24FU, respectively)
are shown for 21 previously therapy-naive chronic HCV patients.
Patients 1 to 13 showed an SVR, patients 14 to 21 a viral
nonresponse. (A) Green squares reflect patients with a significant
increase in either HCV-specific proliferation or (B) IFN-c
production after depletion of Treg. White squares reflect the
absence of regulation by Treg. Grey squares reflect missing data.
Histograms to the right show percentages of patients with
significant Treg driven regulation of HCV-specific responses at
the indicated timepoints.
(PDF)
Table S1 Patient characteristics additional patients (n
=23).
(PDF)
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